Valsartan Tablets, USP 80 mg, 90-count bottle (NDC 0591-2168-19), 1000-count bottle (NDC 0591-216...
FDA Drug Recall #D-0987-2018 — Class II — July 16, 2018
Recall Summary
| Recall Number | D-0987-2018 |
| Classification | Class II — Moderate risk |
| Date Initiated | July 16, 2018 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Teva Pharmaceuticals USA |
| Location | North Wales, PA |
| Product Type | Drugs |
| Quantity | 30,793 90-count bottles, 1,158 1000-count bottles |
Product Description
Valsartan Tablets, USP 80 mg, 90-count bottle (NDC 0591-2168-19), 1000-count bottle (NDC 0591-2168-10), Rx Only, Rx Only, Manufactured by: Arrow Pharma (Malta) Ltd. India, Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054
Reason for Recall
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Distribution Pattern
Product was distributed throughout the United States, including Hawaii and Puerto Rico
Lot / Code Information
Lot Numbers: NDC 0591-2168-19 1175947M, 1175948M, 1177115A, 1219361A, 1240434M, 1250704M NDC 0591-2168-10 1177114A, 1219360M, 1250706A
Other Recalls from Teva Pharmaceuticals USA
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0461-2022 | Class II | Doxylamine Succinate and Pyridoxine Hydrochlori... | Jan 18, 2022 |
| D-0520-2022 | Class II | Tretinoin Capsules, 10 mg, 100 count bottle, Rx... | Jan 10, 2022 |
| D-0522-2022 | Class III | Mimvey (estradiol and norethindrone acetate tab... | Jan 7, 2022 |
| D-0521-2022 | Class III | Mimvey (estradiol and norethindrone acetate tab... | Jan 7, 2022 |
| D-0370-2022 | Class II | MethylPREDNISolone Acetate Injectable Suspensio... | Dec 31, 2021 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.